Trimeris (TRMS) Receives Non-Compliance Notification From NASDAQ
Trimeris, Inc. (Nasdaq: TRMS) received a Nasdaq Staff Deficiency Letter stating that the Company was not in compliance with the Nasdaq audit committee requirement for continued listing as set forth in Marketplace Rule 4350 due to the resignation on December 15, 2008 of Director Kevin C. Tang. At the time of his resignation, Mr. Tang served on the Company's audit committee. His resignation was previously announced by the Company on a Form 8-K filed with the Securities and Exchange Commission on December 16, 2008.
Trimeris, Inc. is a biopharmaceutical company engaged in the commercialization of therapeutic agents for the treatment of viral disease. [SM]
Trimeris, Inc. is a biopharmaceutical company engaged in the commercialization of therapeutic agents for the treatment of viral disease. [SM]
You May Also Be Interested In
- DISH Network (DISH) Sued by Networks for 'Commercial Skipping' Feature
- Pfizer (PFE) Axitinib Gets Positive Opinion from CHMP EMA
- JAKKS Pacific (JAKK) Announces 4M Common Tender at $20/Share
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
